Eddingpharm expands portfolio with ACT Biotech assets
HONG KONG – Among the fastest-growing specialty pharmaceutical companies in China, Eddingpharm Inc. has made a move to consolidate domestic and international oncology drug development through a deal that could be worth as much as $95 million.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter